StockGuide AI
Your portfolio
EN RU ES DE IT PT FR
Ticker: NBIX

Neurocrine Biosciences

Biotech Healthcare Drug Manufacturers - Specialty & Generic
Price 156.57
Reco Hold Potential 54 Risk 69 Updated 2026-09-10
Official website

Forecast impact

negative
Target +40.5% target fill 71.2%
Reaction D5 +0.10% · D10 +0.94% market trust
Impact Potential -4 · Risk +3 valid until 2026-09-12

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological and endocrine diseases. Its core products include therapies for conditions such as tardive dyskinesia and endometriosis. The company operates primarily in the healthcare sector, with major revenue sources stemming from product sales and collaborations with other pharmaceutical firms. Neurocrine's commitment to innovation is reflected in its robust pipeline of drug candidates aimed at addressing unmet medical needs.

Investment Profile

The investment profile of Neurocrine Biosciences is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The absence of dividends suggests a reinvestment strategy aimed at long-term value creation. Investors may find the stock suitable for a medium to long-term horizon, with moderate liquidity reflecting its market position.

Category: Biotech Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Investment style: Growth Horizon: Medium-term Company type: Niche Player
Fundamental metrics (experimental) Updated: 2026-09-05
EPS (TTM) — earnings per share for the last 12 months, $
7.05
Revenue QoQ — quarter-over-quarter revenue growth
17.7%
EPS surprise
-15.8%
20d volatility
1.3%
AI recommendation changes
Date Before After Reason
2026-09-06 Sell Hold Mixed performance; high risk with uncertain momentum.
2026-08-29 Hold Sell Weak momentum and EPS surprise raise concerns.
2026-08-27 Sell Hold Strong revenue growth, but EPS surprise raises concerns.
Analyst forecasts
Date Analyst Action Target Price Then
2026-09-08 RBC Capital Update — → 198 155.655
2026-08-13 Bernstein Target Lowered 221 → 218 156.49
2026-08-13 Morgan Stanley Target Lowered 196 → 182 156.49
News Page 1 of 1

Nothing yet